Nanoengineering-armed oncolytic viruses drive antitumor response: progress and challenges

Area of Science:

• Oncology
• Nanomedicine
• Virology

Background:

• Oncolytic viruses (OVs) are a promising cancer therapy modality, selectively targeting and lysing tumor cells to induce cell death and tumor eradication.
• Traditional OV therapy faces limitations in viral circulation stability and tumor targeting, impacting clinical safety and efficacy.
• Nanoengineering offers solutions to overcome these limitations, enhancing OV performance.

Purpose of the Study:

• To provide a comprehensive analysis of engineered oncolytic viruses (OVs) for cancer therapy.
• To explore the mechanisms by which engineered OVs suppress tumor progression.
• To review the synergy between nanomaterials, nanotechnologies, and OVs, and identify future challenges and strategies.

Main Methods:

• Review of existing literature on oncolytic viruses and their antitumor mechanisms.
• Analysis of nanoengineering strategies applied to OVs, including nanomaterial selection and nanotechnological integration.
• Identification and discussion of current challenges and proposed solutions in the field of engineered OVs.

Main Results:

• Engineered OVs demonstrate enhanced stability and tumor-targeting capabilities compared to traditional OVs.
• The combination of nanomaterials and nanotechnologies with OVs offers innovative approaches for novel virus design.
• Understanding the multifaceted mechanisms of engineered OVs is crucial for optimizing their antitumor response.

Conclusions:

• Nanoengineered oncolytic viruses represent a significant advancement in cancer therapy, offering improved safety and efficacy.
• Continued research into the synergy of nanomaterials and OVs is essential for developing next-generation cancer treatments.
• Addressing current challenges through strategic innovation will pave the way for the broader application of engineered OVs.